Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Escudier

Showing results (21-30 of 362) with videos related to

Pageof 37
Sort By:
European Urology|July 18, 2015
Sorafenib-Sunitinib Sequence: The Jury Is OutLaurence Albiges, Bernard Escudier
Current Opinion in Urology|July 9, 2015
Current and future strategies in nonclear-cell metastatic renal cell carcinomaLaurence Albiges, Bernard Escudier
Medecine Sciences : M/S|September 16, 2008
[Revolution in treatment of renal carcinoma: molecular rational and clinical approach]Bernard Escudier, Marine Gross-Goupil
Oncology (Williston Park, N.Y.)|June 16, 2006
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinomaMartin E Gore, Bernard Escudier
Nature Reviews. Clinical Oncology|February 11, 2015
Urological cancer: towards rational post-nephrectomy follow-up guidelines in RCCJean-Jacques Patard, Bernard Escudier
Expert Review of Anticancer Therapy|December 13, 2005
Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinomaEmilie Viey, Catherine Laplace, Bernard Escudier
The New England Journal of Medicine|November 8, 2018
Sunitinib Alone or after Nephrectomy in Renal CancerBernard Escudier, Simon Thezenas, Arnaud Méjean
Expert Review of Anticancer Therapy|September 6, 2018
Treating patients with renal cell carcinoma and bone metastasesAnnalisa Guida, Bernard Escudier, Laurence Albiges
Expert Review of Anticancer Therapy|October 18, 2008
Bevacizumab: direct anti-VEGF therapy in renal cell carcinomaBernard Escudier, Jan Cosaert, Pavel Pisa
European Urology|September 19, 2013
Do the sites of metastases provide additional information regarding prognosis and biology in renal cell carcinoma?Guru Sonpavde, Sunil Sudarshan, Bernard Escudier
Pageof 37

Showing results (21-30 of 362) with videos related to

Sort By:
Pageof 37
European Urology|July 18, 2015
Sorafenib-Sunitinib Sequence: The Jury Is OutLaurence Albiges, Bernard Escudier
Current Opinion in Urology|July 9, 2015
Current and future strategies in nonclear-cell metastatic renal cell carcinomaLaurence Albiges, Bernard Escudier
Medecine Sciences : M/S|September 16, 2008
[Revolution in treatment of renal carcinoma: molecular rational and clinical approach]Bernard Escudier, Marine Gross-Goupil
Oncology (Williston Park, N.Y.)|June 16, 2006
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinomaMartin E Gore, Bernard Escudier
Nature Reviews. Clinical Oncology|February 11, 2015
Urological cancer: towards rational post-nephrectomy follow-up guidelines in RCCJean-Jacques Patard, Bernard Escudier
Expert Review of Anticancer Therapy|December 13, 2005
Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinomaEmilie Viey, Catherine Laplace, Bernard Escudier
The New England Journal of Medicine|November 8, 2018
Sunitinib Alone or after Nephrectomy in Renal CancerBernard Escudier, Simon Thezenas, Arnaud Méjean
Expert Review of Anticancer Therapy|September 6, 2018
Treating patients with renal cell carcinoma and bone metastasesAnnalisa Guida, Bernard Escudier, Laurence Albiges
Expert Review of Anticancer Therapy|October 18, 2008
Bevacizumab: direct anti-VEGF therapy in renal cell carcinomaBernard Escudier, Jan Cosaert, Pavel Pisa
European Urology|September 19, 2013
Do the sites of metastases provide additional information regarding prognosis and biology in renal cell carcinoma?Guru Sonpavde, Sunil Sudarshan, Bernard Escudier
Pageof 37